Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment
- PMID: 15477718
- DOI: 10.1159/000080742
Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment
Abstract
Somatostatin receptors are expressed in selected human cancers. They are particularly frequently expressed in gastroenteropancreatic neuroendocrine tumors (GEP NET), including both primaries and metastases. The density is often high, the distribution is usually homogeneous. While various somatostatin receptor subtypes can be expressed in these tumors, sst2 is clearly predominant. These receptors represent the molecular basis for a number of clinical applications, including symptomatic therapy with cold octreotide in hormone-secreting GEP NET, in vivo diagnostic with Octreoscan to evaluate the extend of the disease, and 90Y-DOTATOC radiotherapy. GEP NET can, however, express peptide receptors other than somatostatin receptors: insulinomas have more glucagon-like peptide 1 receptors than somatostatin receptors, gut NET (carcinoids) may also express cholecystokinin 2, bombesin or vasoactive intestinal peptide receptors. Often, several of these peptide receptors are expressed simultaneously in GEP NET, providing a molecular basis for in vivo multireceptor targeting of those tumors.
Similar articles
-
Peptide receptor expression in GEP-NET.Virchows Arch. 2007 Aug;451 Suppl 1:S47-50. doi: 10.1007/s00428-007-0443-2. Epub 2007 Aug 8. Virchows Arch. 2007. PMID: 17684767 Review.
-
Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting.Eur J Nucl Med Mol Imaging. 2002 Jul;29(7):855-62. doi: 10.1007/s00259-002-0794-5. Epub 2002 Apr 20. Eur J Nucl Med Mol Imaging. 2002. PMID: 12111125
-
[The somatostatin receptor family--a window against new diagnosis and therapy of cancer].Tidsskr Nor Laegeforen. 2002 Feb 20;122(5):487-91. Tidsskr Nor Laegeforen. 2002. PMID: 11961977 Review. Norwegian.
-
Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.Gastroenterology. 2010 Sep;139(3):742-53, 753.e1. doi: 10.1053/j.gastro.2010.07.002. Epub 2010 Jul 13. Gastroenterology. 2010. PMID: 20637207 Review.
-
Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.Eur J Nucl Med Mol Imaging. 2003 May;30(5):781-93. doi: 10.1007/s00259-003-1184-3. Epub 2003 Apr 18. Eur J Nucl Med Mol Imaging. 2003. PMID: 12707737 Review.
Cited by
-
Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [111In]In-Radioligands: Synthesis and Preclinical Profile.Int J Mol Sci. 2024 Feb 5;25(3):1921. doi: 10.3390/ijms25031921. Int J Mol Sci. 2024. PMID: 38339198 Free PMC article.
-
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms.Cancers (Basel). 2023 Jul 4;15(13):3483. doi: 10.3390/cancers15133483. Cancers (Basel). 2023. PMID: 37444593 Free PMC article. Review.
-
Long-term prognostic factors for PRRT in neuroendocrine tumors.Front Med (Lausanne). 2023 Jun 9;10:1169970. doi: 10.3389/fmed.2023.1169970. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37359009 Free PMC article.
-
PET/MRI imaging in neuroendocrine neoplasm.Abdom Radiol (NY). 2023 Dec;48(12):3585-3600. doi: 10.1007/s00261-022-03757-1. Epub 2022 Dec 16. Abdom Radiol (NY). 2023. PMID: 36525051 Review.
-
[68Ga]Ga-DATA5m-LM4, a PET Radiotracer in the Diagnosis of SST2R-Positive Tumors: Preclinical and First Clinical Results.Int J Mol Sci. 2022 Nov 23;23(23):14590. doi: 10.3390/ijms232314590. Int J Mol Sci. 2022. PMID: 36498918 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
